Consequently, enrichment for gliomas with the compilation of molecular biomarkers (TP53 WT, MDM2 WT, and MGMT negative) was still unable to fully distinguish between therapeutic responders and non-responders (Fig. 4B). The gene discussed is MGMT; the disease is central nervous system cancer.